1. Nissen SE, Wolski K.Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med2007;356:2457–71.
2.
2. Home PD, Pocock SJ, Beck-Nielsen H et al. Rosiglitazone Evaluated for Cardiovascular Outcomes - an interim analysis. N Engl J Med2007; epub June 5, 2007.
3.
3. Nathan DM.Rosiglitazone and cardiotoxicity -weighing the evidence. N Engl J Med2007; epub June 5, 2007.
4.
4. Psaty BM, Furberg CD.The record on rosiglitazone and the risk of myocardial infarction. N Engl J Med2007;356:2522–4.
5.
5. Kahn SE, Haffner SM, Heise MA. et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med2006;355:2427–43.
6.
6. UK Prospective Diabetes Study Group.Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 Diabetes (UKPDS 34). Lancet1998;352:854–65.
7.
7. Gerstein HC, Yusuf S, Bosch J. et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet2006;368:1096–105.
